Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Kindly Medical Instruments Co., Ltd. (1501.HK)
Shanghai, CN
Shanghai Kindly Medical Instruments Co., Ltd., founded in 2006 and based in Shanghai, China, focuses on the research, development, production, and international sales of cardiovascular interventional medical devices. The company's products reach customers across Mainland China, Europe, the United States, and various other global regions. Its comprehensive range of interventional instruments includes guiding catheters, which facilitate the introduction of balloon catheters, guidewires, or other therapeutic tools; micro catheters, offering support for guidewire placement; and guidewires themselves, integral to percutaneous transluminal angioplasty (PTA) surgical procedures. The portfolio also features angiography catheters for injecting contrast media and fluids, along with Y-connector packs specifically designed for PTCA surgery. Further product offerings comprise inflation devices, essential for balloon inflation during vessel dilation or stent deployment; single-use manifolds and manifold kits; and pressure bandages utilized for compression hemostasis. The company additionally manufactures single-use angiography syringes, stopcocks for surgical pressure monitoring, sterile Seldinger needles for arterial puncture, introducer sets, single-use pressure transducers, extension tubes for pressure monitoring, and introducer tool kits employed in percutaneous vertebroplasty. Beyond these specialized tools, Shanghai Kindly Medical Instruments provides a variety of medical accessories, such as check valves, needle-free connectors, male Luer locks, bi-stoppers, Heparian caps, flush devices, and flow regulators. Its broader product selection covers items like joint intervention kits, disposable respirator masks, vaginal dilators (for examinations), Foley catheters, infusion pumps, disposable automatic umbilical cord clamps, single-use infusion connectors and accessories, and burette infusion sets (without needles). Serving medical device manufacturers and other clients, the company operates as a subsidiary of Shanghai Kindly Enterprise Development Group Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.06% | +1.06% | -12.65% | +12.27% | +14.59% | +14.74% | +40.70% | +29.32% | -18.87% | +27.41% | +27.41% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+25.1% ★ Q4'25: +46.3% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%+18.9% ★ Q4'25: +56.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+24.3% ★ Q4'25: +35.1% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+24.2% ★ Q4'25: +23.3% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+10.8% ★ Q4'25: +24.8% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.9% Q4'25: +0.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×2.03× Q4'25: 0.92× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
286.46M
est: 258.37M (+10.9%)
|
358.43M
est: 487.29M (-26.4%)
|
464.68M
est: 514.47M (-9.7%)
|
585.88M
est: 695.06M (-15.7%)
|
752.84M
est: 749.18M (+0.5%)
|
851.95M
est: 978.64M (-12.9%)
|
1.07B
est: 1.02B (+4.0%)
|
1.27B
1.27B – 1.27B
+24.0% YoY
|
1.45B
1.45B – 1.45B
+14.1% YoY
|
1.67B
1.67B – 1.67B
+14.8% YoY
|
| EBITDA |
132.38M
est: 84.53M (+56.6%)
|
143.23M
est: 155.03M (-7.6%)
|
168.81M
est: 205.81M (-18.0%)
|
159.99M
est: 288.55M (-44.6%)
|
225.88M
est: 234.88M (-3.8%)
|
255.43M
est: 306.82M (-16.7%)
|
353.06M
est: 321.22M (+9.9%)
|
398.31M
398.31M – 398.31M
+24.0% YoY
|
454.57M
454.57M – 454.57M
+14.1% YoY
|
522.01M
522.01M – 522.01M
+14.8% YoY
|
| EBIT |
113.74M
est: 70.70M (+60.9%)
|
125.35M
est: 133.77M (-6.3%)
|
144.64M
est: 177.59M (-18.6%)
|
129.34M
est: 248.98M (-48.1%)
|
178.32M
est: 188.93M (-5.6%)
|
212.64M
est: 246.80M (-13.8%)
|
258.29M
est: 258.38M (0.0%)
|
320.39M
320.39M – 320.39M
+24.0% YoY
|
365.64M
365.64M – 365.64M
+14.1% YoY
|
419.89M
419.89M – 419.89M
+14.8% YoY
|
| Net Income |
99.61M
est: 85.87M (+16.0%)
|
121.35M
est: 117.16M (+3.6%)
|
142.96M
est: 155.54M (-8.1%)
|
131.71M
est: 161.37M (-18.4%)
|
156.46M
est: 162.13M (-3.5%)
|
191.91M
est: 181.51M (+5.7%)
|
218.79M
est: 201.45M (+8.6%)
|
248.32M
248.32M – 248.32M
+23.3% YoY
|
284.05M
284.05M – 284.05M
+14.4% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
58.13M
est: 51.28M (+13.4%)
|
57.44M
est: 68.37M (-16.0%)
|
79.07M
est: 90.77M (-12.9%)
|
120.68M
est: 127.26M (-5.2%)
|
166.82M
est: 162.05M (+2.9%)
|
199.61M
est: 211.69M (-5.7%)
|
265.84M
est: 221.62M (+20.0%)
|
274.81M
274.81M – 274.81M
+24.0% YoY
|
313.63M
313.63M – 313.63M
+14.1% YoY
|
360.16M
360.16M – 360.16M
+14.8% YoY
|
| EPS |
0.79
est: 0.50 (+57.0%)
|
0.73
est: 0.69 (+5.8%)
|
0.86
est: 1.06 (-18.5%)
|
0.79
est: 1.13 (-30.2%)
|
0.89
est: 0.94 (-5.4%)
|
1.10
est: 1.16 (-5.1%)
|
1.26
est: 1.17 (+7.7%)
|
1.44
1.44 – 1.44
+23.3% YoY
|
1.65
1.65 – 1.65
+14.4% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 215.5K | 0.39% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 11.9K | 0.44% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 55.4K | 0.28% |
| 4 | Avantis Emerging Markets Equity UCITS ETF USD Acc AVEM.L | 0.00% | 788.27 | 0.35% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dongke Liang | Executive Chairman of the Board & GM | 2M | — |
| Yuan Song | Deputy GM, Joint Company Secretary & Non-Executive Director | 1M | — |
| Sen Lin | Vice GM & Executive Director | 1M | male |
| Shui Bing Leung | Joint Company Secretary | — | female |
| Yan Zhao | Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1501.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
